新闻BenzingaHUTCHMED Receives China National Medical Products Administration Simultaneous Approval For Two New Drug Applications For Syvik Oral Small Molecule Inhibitor Targeting Spleen Tyrosine Kinase HUTCHMED Receives China National Medical Products Administration Simultaneous Approval For Two New Drug Applications For Syvik Oral Small Molecule Inhibitor Targeting Spleen Tyrosine Kinase Benzinga 2026.11.19 10:10 (GMT+0) 在Benzinga上打开 其他新闻 两巨鲸解质押231万枚SOL并存入Coinbase Prime,价值约1.694亿美元 蚂蚁国际推出Whale编排协议,以连接代币化存款与代币化货币市场基金 新加坡金管局成功发行约7700万美元代币化票据,并通过批发型CBDC结算 “前所未有的成果”:Greg Brockman 表示,AMD 借助 OpenAI 将一年的芯片进展压缩到 5 个月内 Sygnum:2027年比特币现货与期货套利策略回报预计将高于美国国债 VisionWave Holdings(VWAV)股票盘后下跌18.74%:原因如下